(Total Views: 870)
Posted On: 11/02/2020 9:51:30 AM
Post# of 154834
The reality is, potential CD12 participants don't even have to make that type of choice since the trial criteria already allows Remdisivir, Plasma, etc. as SOC in either placebo/treatment arm.
https://clinicaltrials.gov/ct2/show/NCT04347239
For this reason, we should all expect CD12 enrolment to increase significantly in the next couple of weeks. As others have posted prior, the enrollment strategy should simply be to target the many s/c on SOC who are not improving as they have NOTHING TO LOSE by enrolling in CD12. There's really no hard choice they have to make.
On the other hand, if enrollment still struggles at the end of November I'd interpret that as a warning that something isn't right and perhaps other extreme strategies should be put back on the table (e.g. un-blinding interim data w/ penalty). Otherwise our COVID efforts risk dying on the vine.
Quote:
Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.
https://clinicaltrials.gov/ct2/show/NCT04347239
For this reason, we should all expect CD12 enrolment to increase significantly in the next couple of weeks. As others have posted prior, the enrollment strategy should simply be to target the many s/c on SOC who are not improving as they have NOTHING TO LOSE by enrolling in CD12. There's really no hard choice they have to make.
On the other hand, if enrollment still struggles at the end of November I'd interpret that as a warning that something isn't right and perhaps other extreme strategies should be put back on the table (e.g. un-blinding interim data w/ penalty). Otherwise our COVID efforts risk dying on the vine.
(13)
(1)
